In the pipeline: encorafenib and binimetinib in BRAF-mutated melanoma.

In the pipeline: encorafenib and binimetinib in BRAF-mutated melanoma. Clin Adv Hematol Oncol. 2017 Oct;15(10):745-747 Authors: Flaherty K PMID: 29040252 [PubMed - in process]
Source: Clinical Advances in Hematology and Oncology - Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research